Abstract
Further clinical trials are proposed for the 5–15% of hypothyroid patients who are dissatisfied with thyroxine (T4) monotherapy. Those responding to combination therapy [T4 plus triiodothyronine (T3)] will show suggestive biochemistry and abnormal reflexes. Those with Hashimoto's disease and very high anti-thyroid peroxidase (anti-TPO) thyroid antibody levels may benefit from total thyroidectomy. The remainder have negative clinical and laboratory findings and require supportive management.
Original language | English |
---|---|
Pages (from-to) | 536-538 |
Number of pages | 3 |
Journal | Trends in Endocrinology and Metabolism |
Volume | 33 |
Issue number | 8 |
Early online date | 2022 |
DOIs | |
Publication status | Published - Aug 2022 |